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Background: A beneficial effect on cardiovascular risk may be obtained by improving 
lipid-related serum lipoprotein functions such as high-density lipoproteins (HDLs) cholesterol 
efflux capacity (CEC) and serum cholesterol loading capacity (CLC) and by reducing proprotein 
convertase subtilisin kexin type 9 (PCSK9), independently of lipoprotein concentrations.
Aim: We aimed to evaluate the effect of an innovative nutraceutical (NUT) combination contain-
ing red yeast rice (monacolin K 3.3 mg), berberine 531.25 mg and leaf extract of Morus alba 
200 mg (LopiGLIK®), on HDL-CEC, serum CLC and on circulating PCSK9 levels.
Materials and methods: Twenty three dyslipidemic subjects were treated for 4 weeks with 
the above NUT combination. HDL-CEC was measured using specific cell-based radioisotopic 
assays; serum CLC and PCSK9 concentrations were measured fluorimetrically and by enzyme-
linked immunosorbent assay, respectively.
Results: The NUT combination significantly reduced plasma level of the total cholesterol and 
low-density lipoprotein cholesterol (-9.8% and -12.6%, respectively). Despite no changes 
in HDL-cholesterol, the NUT combination improved total HDL-CEC in 83% of the patients, 
by an average of 16%, as a consequence of the increase mainly of the ATP-binding cassette 
A1-mediated CEC (+28.5%). The NUT combination significantly reduced serum CLC (-11.4%) 
while it did not change PCSK9 plasma levels (312.9±69.4 ng/mL vs 334.8±103.5 mg/L, before 
and after treatment, respectively).
Conclusion: The present NUT combination improves the serum lipoprotein functional pro-
file providing complementary beneficial effects, without any detrimental increase of PCSK9 
plasma levels.
Keywords: nutraceutical, monacolin K, berberine, Morus alba, HDL, cholesterol efflux 
capacity, macrophage, PCSK9
Introduction
In moderate hypercholesterolemia, an available alternative to pharmacological therapy 
is the use of innovative nutritional compounds, the so-called nutraceuticals (NUTs), 
as the recent guidelines recommend.1 Several NUTs have shown significant effects 
in improving plasma lipid profile, by reducing total cholesterol (TC) and low-density 
lipoprotein cholesterol (LDL-C) and, in some cases, by moderately increasing high-
density lipoprotein cholesterol (HDL-C), with a potential positive impact on cardio-
vascular (CV) risk.2,3
However, the mere improvement of quantitative lipid profile may not be the only 
target to obtain optimal CV benefits, as exemplified by the failure of the hypothesis 
that HDL-C raising therapy would reduce CV risk.4 Therefore, recent research on HDL 
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has moved to the evaluation of their functional properties, 
in particular their ability to remove excess cholesterol from 
macrophages of the artery wall, by promoting the process of 
cholesterol efflux to HDL. HDL cholesterol efflux capacity 
(CEC) has been inversely associated with the prevalence of 
coronary heart disease5 and the incidence of CV events.6,7 In 
addition, it displayed the potential to improve risk stratifica-
tion beyond the traditional factors, including plasma HDL-C 
concentrations.8
Although HDL-CEC may explain the link between HDL 
function and atherosclerosis, it only reflects the movement of 
cholesterol out of cells, while lipid trafficking is bidirectional.9 
Serum capacity to promote cholesterol uptake and accumula-
tion in macrophages (cholesterol loading capacity [CLC]) 
might represent, in this context, an additional functional 
lipid-related parameter that takes into account the movement 
of cholesterol from lipoproteins into the cells.9 Such ability 
relies on the contribution of all lipoproteins present in the 
serum, in terms of both concentration and function, and it 
can be considered an index of the serum pro-atherogenic 
potential. In support of this idea, our research team and others 
have previously demonstrated that serum CLC is increased in 
pathological conditions associated to increased CV risk.9–11
An additional identified player of cholesterol homeostasis 
maintenance is the proprotein convertase subtilisin kexin type 
9 (PCSK9), able to degrade the hepatic LDL receptor, result-
ing in elevated plasma LDL-C concentrations.12 Nevertheless, 
the activity of PCSK9 goes beyond LDL-C modulation and it 
involves other aspects of cholesterol homeostasis relevant for 
the pathogenesis of atherosclerosis.12,13 The results of a cohort 
study indicate, in fact, that circulating levels of PCSK9 are 
associated with CV events,14 atherosclerosis progression,15 
arterial stiffness,16 independently of plasma LDL-C concen-
trations. Among the possible direct pro-atherogenic effects 
of PCSK9, there is the inhibition of the cholesterol efflux 
process promoted by the transporter ATP-binding cassette 
A1 (ABCA1) in macrophages, as we recently demonstrated.17 
Based on these observations, the increase of HDL-CEC, the 
inhibition of serum CLC and the reduction of PCSK9 plasma 
levels may be a multi-target strategy to counteract cholesterol 
accumulation in macrophage and foam cell formation.
Given the relevance of the above parameters with respect 
to CV risk,18,19 as well as the poor data available on the impact 
of nutritional approaches on these lipoprotein functional 
properties and, even less, on plasma PCSK9 levels,20–24 the 
aim of the present work was to evaluate the effect of a novel 
NUT combination25 on HDL-CEC, serum CLC and circulat-
ing PCSK9 levels.
Materials and methods
Patients
LopiWEB is a randomized study (NCT02898805), expecting 
to enroll .600 subjects by physicians, designed to assess the 
efficacy of LopiGLIK® (Akademy Pharma, Milano, Italy) in 
real-life. Several regions of Italy are involved in the study 
and data are collected via electronic case report forms on the 
website www.lopiweb.it.
In this work, we studied a subgroup population of 
23 subjects. The inclusion criteria were age between 18 and 
70 years, the presence of metabolic syndrome or moderate 
hypercholesterolemia not requiring immediate statin treat-
ment or statin intolerance. Pregnant, breastfeeding women 
and subjects taking hypolipidemic drugs were excluded from 
the study. The selected patients were not subjected to any 
kind of therapy before the NUT combination treatment. For 
this study, subjects received one pill/day containing a NUT 
combination of 625 mg of Berberis aristata cortex dry extract 
(corresponding to 531.25 mg of berberine), 220 mg of red 
yeast rice powder (corresponding to 3.3 mg of monacolin K) 
and 200 mg of Morus alba leaf dry extract (containing 4 mg 
of 1-deoxynojirimycin) for 16 weeks. During the study, blood 
withdrawal and serum isolation were planned at baseline 
and after 4 and 16 weeks of treatment. Our results refer to 
serum analyses at baseline (T1) and after 4 weeks (T2) of 
treatment.
Serum samples were collected at the University of Naples 
after obtaining written informed consent from participants 
and immediately stored at -80°C. Serum lipid profile was 
assessed by standard laboratory methods. The study was con-
ducted in accordance with the guidelines of the Declaration of 
Helsinki and the study protocol was approved by the Ethics 
Committee of the Federico II University of Naples.
hDl-CeC
HDL-CEC was evaluated through a widely validated iso-
topic technique. In particular, we adopted different cellular 
models expressing the most important transporters involved 
in the promotion of cholesterol efflux to HDL: J774 murine 
macrophages in basal conditions were taken as a model of 
aqueous diffusion (AD); J774 macrophages incubated with 
0.3 mM of a cAMP analog (8-(p-chlorophenylthio)-cAMP; 
Sigma-Aldrich Co, St Louis, MO, USA) to induce ABCA1 
expression, were used as a model of total HDL-CEC 
as previously described.5,26 The ABCA1 contribution was 
measured as the difference between total HDL-CEC and 
AD-CEC.27 Chinese hamster ovary cells transfected or 
not transfected with the human ABCG1 gene were used to 
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evaluate ABCG1-mediated CEC. The specific ABCG1 con-
tribution was calculated as the difference between CEC in 
ABCG1-transfected and not transfected cells.11 In all assays, 
the cells were labeled with [1,2-3H]-cholesterol (PerkinEl-
mer Inc, Waltham, MA, USA) for 24 hours in the presence 
of an inhibitor of the cholesterol esterifying enzyme, acyl-
CoA:cholesterol acyltransferase, to ensure all cholesterol 
was present in the unesterified form. After an equilibration 
period in medium containing 0.2% bovine serum albumin 
(Sigma-Aldrich), the cells were exposed for 4 or 6 hours 
to 1% or 2% (v/v) (depending on the efflux pathway to be 
analyzed) of serum HDL fraction from patients before and 
after NUT combination treatment. HDLs were isolated from 
whole serum by precipitation of the apolipoprotein B (apoB) 
containing lipoproteins with polyethylene glycol as previ-
ously described.28 HDL-CEC was expressed as a percentage 
of the radioactivity released into the medium over the total 
radioactivity incorporated by the cells. A pool of human 
normolipidemic sera was tested in each assay as reference 
standard 1 and its CEC was used to normalize the patient 
samples CEC values from the different experiments (n=3), 
to correct for the inter-assay variability. Each experiment 
was performed in triplicate.
A second pool of human normolipidemic sera as refer-
ence standard 2 was tested in each assay and its CEC was 
the index of the inter-assay variability.
serum ClC
THP-1-derived human macrophages were cultured in 24-well 
plates in the presence of 50 ng/mL of phorbol 12-myristate 
13-acetate (Sigma-Aldrich) for 72 hours to allow the cells 
to differentiate into macrophages. Cells were exposed for 
24 hours to serum collected before and after 4 weeks of treat-
ment with the NUT combination. Whole serum dilution in 
this model was 10% (v/v). Cell cholesterol content was mea-
sured by fluorometric detection in cell lysates.10 An aliquot 
of the cell lysates was used to measure cell protein by the 
modified colorimetric Lowry method.29 CLC was defined 
as macrophage cholesterol content in the cell lysates after 
exposure of cells to serum and was expressed as micrograms 
of cholesterol per milligrams of protein.
Determination of apolipoprotein a 
(apoa)-i sera levels
To evaluate apoA-I concentration in the HDL fraction, 
sera were depleted of the apoB containing lipoproteins by 
precipitation with polyethylene glycol.28 apoA-I was mea-
sured by enzyme-linked immunosorbent assay (ELISA; 
Mabtech, Sweden) following the manufacturer’s instructions. 
The sensitivity ranged from 0.63 to 40 ng/mL with a mini-
mum detectable concentration of 0.2 ng/mL.
Circulating levels of PCsK9
Sera PCSK9 levels were measured by ELISA (R&D Systems, 
Minneapolis, MN, USA) as previously described.30 The 
sensitivity ranged from 0.030 to 0.219 ng/mL with a mini-
mum detectable concentration of 0.096 ng/mL.
statistical analysis
The sample size was calculated a priori by using the G*Power 
software (Düsseldorf, Germany) (selecting two-tailed t-test, 
difference between two dependent means [matched pairs], 
and a priori power analysis), by fixing a power of 0.95 and a 
significance level of 0.05. Statistical analyses were performed 
using GraphPad Prism version 6.0 (GraphPad Software Inc, 
La Jolla, CA, USA). Each sample was run in triplicate. Data 
were expressed as mean ± SD.
Specific pathway-mediated CEC and CLC values at base-
line were compared within treatment groups by using the 
two-tailed Student’s t-test for paired samples, after verifying 
equal variance with the F-test and normal distribution of the 
parameters with the D’Agostino and Pearson omnibus nor-
mality test. Significant differences were defined as p,0.05.
Results
Patients characteristics
The 23 patients enrolled for the study displayed a mean age 
of 55.39±12.7 years and 56.5% of them were males. Base-
line demographic and characteristics of the study population 
are reported in Table 1. Overall, subjects had clinical and 
laboratory parameters within a range of normality except 
Table 1 Baseline subjects’ characteristics
Characteristics N=23
age (years) 55.39±12.7
Male sex (n, %) 13 (56.5%)
Body max index (kg/m2) 27.67±3.5
FPg (mg/dl) 89.72±13.9
sBP (mmhg) 129.68±10.9
DBP (mmhg) 81.59±7.1
TC (mg/dl) 218±36.2
lDl-C (mg/dl) 143±33.0
hDl-C (mg/dl) 50±10.8
Tg (mg/dl) 125±62.4
Note: Data are presented as mean ± sD or n (%).
Abbreviations: FPg, fasting plasma glucose; sBP, systolic blood pressure; 
DBP, diastolic blood pressure; TC, total cholesterol; lDl-C, low-density lipoprotein 
cholesterol; hDl-C, high-density lipoprotein cholesterol; Tg, triglycerides.
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for a slight increase of TC and LDL-C, according to the 
inclusion criteria.
Table 2 shows the lipid profile at baseline and after treat-
ment with the NUT combination. The NUT combination 
significantly reduced the plasma level of TC and of LDL-C 
of about 9.2% and 12.6%, respectively.
Conversely, no differences were observed after treatment 
on plasma HDL-C, triglycerides levels and plasma remnants 
cholesterol calculated by subtracting LDL-C and HDL-C 
from TC31 (25±12.5 mg/dL before treatment vs 23±11.7 mg/
dL after treatment; not significant [ns]).
apoA-I concentration was measured in serum samples 
after precipitation of apoB- containing lipoproteins with 
polyethylene glycol. The NUT combination did not show 
any significant effect on apoA-I concentrations.
hDl-CeC
First, we evaluated the effect of the NUT combination 
on total HDL-CEC of sera from the enrolled subjects in 
a model of cAMP-stimulated J774 macrophages. In these 
conditions, release of cholesterol from cells mainly occurs 
through AD and the ABCA1-mediated processes. Compared 
to baseline, the NUT combination increased total HDL-CEC 
by an average of 16.1% (Figure 1A), improving it in 83% 
of the patients. Since the major contributions to total HDL-
CEC are given by AD and ABCA1, we analyzed these two 
cholesterol efflux pathways individually. We found that the 
NUT combination significantly increased HDL-CEC via both 
ABCA1 and AD, with ABCA1 being increased at a higher 
extent compared to AD (+28.5% and +8.1%, respectively) 
(Figure 1B and C).
Table 2 Effect of NUT combination on serum lipid profile
Baseline
(n=23)
NUT 
combination
(n=23)
Mean 
change %
p-value
TC (mg/dl) 218±36.2 198±31.1 -9.2 ,0.001
lDl-C (mg/dl) 143±33.0 125±23.1 -12.6 ,0.01
hDl-C (mg/dl) 50±10.8 49±11.1 -2 ns
Tg (mg/dl) 125±62.4 116±58.5 -7.2 ns
apoa-i (mg/dl) 128.68±39.68 131.39±45.44 -2 ns
Notes: Data are presented as mean ± SD. Statistical significance was calculated by 
the two-tailed student’s paired t-test.
Abbreviations: TC, total cholesterol; lDl-C, low-density lipoprotein cholesterol; 
hDl-C, high-density lipoprotein cholesterol; Tg, triglycerides; apoa-i, apolipo-
protein A-I; NS, not significant; NUT, nutraceutical.
Figure 1 effect of nUT combination on serum hDl-CeC.
Notes: Total serum hDl-CeC (A), serum hDl-CeC mediated by aBCa1 (B) and by aD (C) in subjects (n=23) at baseline (T1, empty circles) and after (T2, black circles) 
consumption of the nUT combination. each point represents the mean of values obtained from evaluation in triplicate of each serum sample. horizontal lines represent the 
mean (±SD) of values within each subject group. Statistical significance was calculated by the two-tailed Student’s paired t-test. *p,0.05; ***p,0.001.
Abbreviations: CEC, cholesterol efflux capacity; HDL, high-density lipoproteins; ABCA1, ATP-binding cassette transporter A1; AD, aqueous diffusion; NUT, nutraceutical.
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When we evaluated HDL-CEC mediated by ABCG1, 
we could not observe any significant changes induced by 
the NUT combination (before treatment 5.43%±2.21%, 
after treatment 5.07%±2.30%; p= ns). CEC values for all 
the analyzed pathways did not correlate with plasma HDL-C 
levels neither before nor after the consumption of the NUT 
combination (data not shown).
serum ClC
Cell cholesterol content is the result of both cholesterol efflux 
and influx.32 To study the overall serum ability to modulate 
cellular cholesterol content, we evaluated the effect of the 
NUT combination on serum CLC in THP-1-derived human 
macrophages. As shown in Figure 2, the NUT combina-
tion significantly reduced serum capacity of loading cells 
with cholesterol (from 32.15±7.28 to 28.47±6.32 µg of 
cholesterol/mg protein, p,0.05). No correlation was found 
between CLC values and neither plasma LDL-C levels nor 
plasma remnants cholesterol, both before and after the NUT 
combination (data not shown).
effect of nUT combination on circulating 
levels of PCsK9
Since different components of the NUT combination are 
predicted to have opposite effects on PCSK9, berberine 
should decrease while monacolin K should increase PCSK9 
plasma levels, we measured the PCSK9 serum concentrations 
by ELISA assay. The NUT combination did not show 
any significant effect on PCSK9 levels (312.9±69.4 and 
334.8±103.5 ng/mL, respectively; p= ns) (Figure 3).
Discussion
In this study, we investigated the effect of a novel NUT 
combination of berberine, monacolin K, and M. alba extract 
(LopiGLIK®) on serum lipid-related factors involved in the 
protective process of reverse cholesterol transport. Serum 
CEC, serum CLC and serum level of PCSK9 represent factors 
that may directly modulate cholesterol homeostasis in mac-
rophages, the main cellular component of atheroma.33 The 
evaluation of these parameters provides a serum functional 
lipid profile related to CV risk independent of serum lipid 
concentrations.
Consistent with a previous study,25 our results confirm 
that the NUT combination favorably modifies the plasma 
lipid profile in terms of reduction of TC and LDL-C. In the 
present study, the most striking result is that, despite the lack 
of an effect on HDL-C plasma level, the NUT combination 
improves serum HDL-CEC, the main antiatherogenic prop-
erty of these lipoproteins. Thus, the NUT combination appears 
to improve HDL functionality without altering plasma 
HDL-C concentrations. Only few studies have previously 
shown a positive effect of NUTs on HDL-CEC.22,34 Our NUT 
combination increased total HDL-CEC, the cholesterol efflux 
pathway recently identified as a CV risk biomarker and a 
promising target for the prevention and therapies of CV dis-
eases, independently of plasma HDL-C concentrations.4–6
Figure 2 effect of nUT combination on serum ClC.
Notes: ClC of serum from subjects (n=23) at baseline (T1, empty circles) and after 
(T2, black circles) consumption of the nUT combination. each point represents 
the mean of the values obtained from evaluation in triplicate of each serum sample. 
horizontal lines represent the mean (±sD) of values within each subject group. 
Statistical significance was calculated by the two-tailed Student’s paired t-test. 
*p,0.05.
Abbreviations: nUT, nutraceutical; ClC, cholesterol loading capacity.
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Figure 3 effect of nUT combination on plasma levels of PCsK9.
Notes: PCsK9 levels of serum from subjects (n=23) at baseline (T1, empty circles) 
and after (T2, black circles) consumption of the nUT combination. each point 
represents the mean of the values obtained from evaluation in triplicate of each 
serum sample. horizontal lines represent the mean (±sD) of values within each 
subject group. Statistical significance was calculated by the two-tailed Student’s 
paired t-test.
Abbreviations: nUT, nutraceutical; PCsK9, proprotein convertase subtilisin kexin 
type 9 (PCSK9); ns, not significant.
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When we analyzed the individual pathways contributing 
to total efflux, ABCA1 and AD, we found that the increase 
of total CEC was mainly related to the improved process of 
ABCA1-mediated CEC. This cholesterol efflux pathway repre-
sents the main route by which macrophages release cholesterol 
to serum and oppose foam cell formation and atherosclerosis 
progression.35 The improvement of the ABCA1-mediated 
CEC, without an effect on ABCG1-mediated CEC, suggests 
a shift of HDL particles distribution toward lipid-poor pre-β 
HDL specific for the ABCA1 pathway.36,37 Consistent with our 
results, the increase in pre-β HDL may occur independently of 
serum HDL-C.36 In addition, when we measured apoA-I levels 
in apoB-depleted serum, we found that the NUT combina-
tion did not affect even apoA-I concentrations. Our finding 
can be explained by the fact that neither apoA-I nor HDL-C 
serum concentration values reflect the actual serum content of 
pre-β HDL, the specific HDL particles acting as acceptor for 
ABCA1.27,38 Moreover, free apoA-I active as ABCA1 acceptor 
constitutes only about 5% of the circulating apoA-I.39
It may be speculated that the increase in pre-β HDL 
could be related to a NUT-induced production of these 
nascent particles that may involve the stimulation of hepatic 
ABCA1 transporter.40 This NUT effect might be related to 
the presence of monacolin K, given the documented stimu-
lating effect of statins on hepatic ABCA1 both in vitro and 
in vivo.41,42 However, the impact of statin therapy on HDL-
CEC does not appear to be substantial, in agreement with the 
modest effect of statins on HDL-C concentration and on HDL 
subclasses distribution43 and no data on CEC are available 
for berberine and M. alba. A possible effect by berberine 
and M. alba on HDL-CEC cannot be excluded, although no 
literature is available yet in this regard.
The other serum lipoprotein function that we evaluated, 
CLC, is the ability of serum to load macrophages with cho-
lesterol. Treatment with the NUT combination reduced this 
pro-atherogenic potential of serum. Consistent with previous 
observations,11 this effect did not correlate to the reduction 
of plasma LDL-C concentrations. Beyond LDL-C, also 
remnant cholesterol which includes VLDL, namely non-LDL 
and non-HDL-C,31 contributes to macrophage cholesterol 
loading.44 However, we did not observe any changes in 
remnants levels. Most probably, the observed reduced serum 
CLC is related to the combined effect of both decrease on 
LDL levels and the increase of HDL-CEC induced by the 
NUT combination treatment.
A recent study demonstrated that circulating PCSK9 
was associated to carotid atherosclerosis independent of 
the effect on LDL-C plasma level.15 More recently, we 
demonstrated that PCSK9 in macrophages directly inhibits 
the efflux of cholesterol specifically mediated by ABCA1.17 
This effect would counteract the beneficial increase in 
ABCA1-mediated CEC induced by our NUT combination. 
We therefore evaluated if our present NUT approach could 
modulate serum functionality not only in terms of CEC and 
CLC, but also of plasma PCSK9 concentrations.
In contrast to the results reported with monacolin K 
alone,46 our results indicate that our NUT combination did 
not modify PCSK9 plasma levels. We may speculate that 
the effect of monacolin K, the statin produced by Monascus 
purpureus present in our NUT combination, toward an 
increase of plasma PCSK9,46 may be counteracted by the 
presence of berberine, a known negative modulator of PCSK9 
concentration in plasma.45,47 In addition, extracts from dried 
immature M. alba fruits have been recently shown to have 
an inhibitory activity on PCSK9.48
This result indicates an additional potential benefit 
of a NUT combination compared to the statin single 
administration.
Limitations of the study
The small number of patients in this study, with a relatively 
wide range of age, limited the potential for detailed statistical 
analyses, but it provides a picture of a real-life population. 
In addition, our study population was large enough to meet 
the required statistical power to demonstrate the differences 
in both HDL-CEC and serum CLC. It is worth pointing out 
that the variation of the measured parameters was consistently 
observed in ~80% of the examined subjects. As this is the 
first study evaluating the effect of a NUT combination on 
lipoprotein functions, despite the modest effect, it provides 
an important direction for further confirmatory studies in a 
larger group of subjects.
Conclusion
Our results demonstrate that, despite the lack of effect on 
HDL plasma concentrations, our NUT combination may 
improve lipoprotein protective functions providing comple-
mentary beneficial effects for CV risk prevention, particularly 
useful in moderate dyslipidemic subjects.
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